一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Oncogenesis >>article
Oncogenesis

Oncogenesis

IF: 5.9
Download PDF

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer

Published:2 January 2023 DOI: 10.1038/s41389-022-00446-y PMID: 36593255
Yongming Fu, Tuoyu Cao, Xiaorui Zou, Yubing Ye, Youhong Liu, Yuchong Peng, Tanggang Deng, Linglong Yin, Xiong Li

Abstract

Oncogenic activation of PI3K/AKT signaling pathway, together with epigenetic aberrations are the characters of castration-resistant prostate cancer (CRPC). UHRF1 as a key epigenetic regulator, plays a critical role in prostate cancer (PCa) development, and its expression is positively correlated with the degree of malignancy. In this present study we investigated the potential regulatory mechanism of AKT1 on UHRF1, and further validated the in vitro and in vivo anticancer efficacy of AKT phosphorylation inhibitor MK2206 in combination with abiraterone. Both UHRF1 and p-AKT aberrantly overexpressed in the abiraterone-resistant PCa cells. Further studies revealed that AKT1 protein interacts with UHRF1, and AKT1 directly phosphorylates UHRF1 via the site Thr-210. MK2206 induced UHRF1 protein degradation by inhibiting AKT1-induced UHRF1 phosphorylation, and then reduced the interaction between UHRF1 and deubiquitinase USP7, while promoted the interaction between UHRF1 and E3 ubiquitin protein ligase BTRC. MK2206 significantly promoted the sensitivity of abiraterone-refractory PCa cells and xenografts to abiraterone by decreasing UHRF1 protein level, and reversed the phenotype of NEPC, evently induced cellular senescence and cell apoptosis. Altogether, our present study for the first time revealed a novel molecular mechanism of abiraterone resistance through PI3K/AKT-UHRF1 pathway, and provided a novel therapeutic modality by targeting PI3K/AKT1 to promote the drug sensitivity of abiraterone in PCa patients.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$3568.00
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$3568.00
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$3568.00
MG-132 133407-82-6 C26H41N3O5 427 suppliers $11.00-$3568.00

Similar articles

IF:98.4

Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.

The Lancet Neil E Fleshner, M Scott Lucia,etc Published: 24 March 2012
IF:0

Resistance to trimethoprim-sulfamethoxazole.

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America G. Eliopoulos,?P. Huovinen,etc Published: 1 June 2001
周宁县| 工布江达县| 黎川县| 鄂温| 珲春市| 齐河县| 洞口县| 呼和浩特市| 岳西县| 长寿区| 宁城县| 商水县| 高雄市| 平定县| 南雄市| 陆川县| 特克斯县| 平邑县| 兴山县| 潞西市| 苏尼特右旗| 巴中市| 玉门市| 浏阳市| 景德镇市| 安顺市| 黄石市| 武义县| 沙湾县| 定西市| 聊城市| 两当县| 崇左市| 抚顺市| 天等县| 滦南县| 邵阳县| 潼关县| 新民市| 汝州市| 万宁市|